Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma—Are There Any Favorable Risk Patients?
- 1 July 2021
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 206 (1), 4-6
- https://doi.org/10.1097/ju.0000000000001656
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and LymphadenectomyJournal of Clinical Oncology, 2018
- Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell CarcinomaEuropean Urology, 2018
- Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United StatesEuropean Urology Oncology, 2018
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2018
- Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trialThe Lancet Oncology, 2016
- Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive NephrectomyEuropean Urology, 2016
- Surgical Outcomes After Cytoreductive Nephrectomy With Inferior Vena Cava ThrombectomyUrology, 2014
- Laparoscopic Cytoreductive Nephrectomy: A Three-Center Retrospective AnalysisJournal of Endourology, 2010
- Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomyBJU International, 2010
- Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, 2004